1,6-二苯基己烷-3,4-二酮 | 6958-90-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 1,6-二苯基己烷-3,4-二酮
• 英文名称: 1,6-Diphenyl-hexan-3,4-dion
• 英文别名: 1,6-Diphenylhexane-3,4-dione
• CAS: 6958-90-3
• 化学式: C₁₈H₁₈O₂
• 分子量: 266.34
• InChiKey: UBGBMZWHIZIPRK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  20
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  34.1
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1,6-二苯基己烷-3,4-二酮 在 4,5-二甲基-3-(2-氧代-2-苯基乙基)噻唑鎓氯化物 作用下， 以82%的产率得到3-苯基丙酸
  参考文献：
  名称：

  Crosslink Breakers for Preservation of Biological Substances

  摘要：

  一种用于体液、蛋白质、细胞和组织的防腐剂，包括一种有效量的AGE交联断裂剂，用于预防高级糖基化终产物的形成。AGE交联断裂剂包括结构（1）中的化合物： 其中V、W、X、Y和Z是适用于杂环卡宾或卡宾前体框架的任何原子，包括B、C、O、N、S、Se、P和As在任何化学上可行的氧化态； 其中Q、R、M、T和U是任何原子或取代基，包括但不限于H、CLn、NLn、PLn、OLn、SLn、SeLn、LnCl、LnBr、LnI，其中L是任何原子、取代基或基团，n是任何整数，使得Q、R、M、T和U可以访问所有化学上可行的氧化态；以及 其中G包括任何带电的对离子，包括但不限于那些来源于C、O、N、B、Al、S、Se、Cl、Br、I在任何化学上可行的氧化态。

  公开号：

  US20150099260A1
• 作为产物：
  描述：

  3-苯丙酸乙酯 在 乙醚 、 alkali metal 、 氧气 作用下， 生成 1,6-二苯基己烷-3,4-二酮
  参考文献：
  名称：

  Scheibler; Emden, Justus Liebigs Annalen der Chemie, 1923, vol. 434, p. 283

  摘要：

  DOI：

文献信息

• Synthesis of 2,5-dihydrofurans via alkylidene carbene insertion reactions
  作者：Louise F. Walker、Ahmed Bourghida、Stephen Connolly、Martin Wills

  DOI：10.1039/b111097g

  日期：2002.3.25

  The insertion reaction of alkylidene carbenes is demonstrated to be an effective method for the synthesis of 2,5-dihydrofuran ring systems. The best results have been obtained on substrates containing electron-withdrawing substituents, which appear less prone to the competing rearrangement reaction. This insight has led to the development of a new method for the synthesis of the core structure of the squalestatin–zaragozic acid natural products.

  已证明，烷叉亚甲基卡宾的插入反应是合成2,5-二氢呋喃环体系的有效方法。在含有吸电子取代基的底物上获得了最佳结果，这些底物似乎不太容易发生竞争性的重排反应。这一认识促进了合成角鲨烯内酯-扎戈唑酸天然产物核心结构新方法的发展。
• Reduction of 1,2-Dicarbonyl Compounds Mediated by the Combination of Phosphine and Lewis Acid
  作者：Yukihiko Hashimoto、Satoshi Kikuchi

  DOI：10.1055/s-2004-825581

  日期：——

  The combination of Ph3P/AlBr3 effectively promoted the reduction of several 1,2-dicarbonyl compounds in the presence of water (1.0 equiv) and the corresponding α-hydroxy carbonyl compounds were obtained in good yields.

  Ph3P/AlBr3的组合有效促进了在水（1.0当量）存在下几种1,2-二羰基化合物的还原，并获得了相应的α-羟基羰基化合物，产率良好。
• Dicyclic and Tricyclic Diaminopyrimidine Derivatives as Potent Inhibitors of <i>Cryptosporidium parvum</i> Dihydrofolate Reductase: Structure-Activity and Structure-Selectivity Correlations
  作者：Richard G. Nelson、Andre Rosowsky

  DOI：10.1128/aac.45.12.3293-3303.2001

  日期：2001.12

  A structurally diverse library of 93 lipophilic di- and tricyclic diaminopyrimidine derivatives was tested for the ability to inhibit recombinant dihydrofolate reductase (DHFR) cloned from human and bovine isolates of Cryptosporidium parvum (J. R. Vásquez et al., Mol. Biochem. Parasitol. 79:153–165, 1996). In parallel, the library was also tested against human DHFR and, for comparison, the enzyme from Escherichia coli . Fifty percent inhibitory concentrations (IC ₅₀ s) were determined by means of a standard spectrophotometric assay of DHFR activity with dihydrofolate and NADPH as the cosubstrates. Of the compounds tested, 25 had IC ₅₀ s in the 1 to 10 μM range against one or both C. parvum enzymes and thus were not substantially different from trimethoprim (IC ₅₀ s, ca. 4 μM). Another 25 compounds had IC ₅₀ s of <1.0 μM, and 9 of these had IC ₅₀ s of <0.1 μM and thus were at least 40 times more potent than trimethoprim. The remaining 42 compounds were weak inhibitors (IC ₅₀ s, >10 μM) and thus were not considered to be of interest as drugs useful against this organism. A good correlation was generally obtained between the results of the spectrophotometric enzyme inhibition assays and those obtained recently in a yeast complementation assay (V. H. Brophy et al., Antimicrob. Agents Chemother. 44:1019–1028, 2000; H. Lau et al., Antimicrob. Agents Chemother. 45:187–195, 2001). Although many of the compounds in the library were more potent than trimethoprim, none had the degree of selectivity of trimethoprim for C. parvum versus human DHFR. Collectively, the results of these assays comprise the largest available database of lipophilic antifolates as potential anticryptosporidial agents. The compounds in the library were also tested as inhibitors of the proliferation of intracellular C. parvum oocysts in canine kidney epithelial cells cultured in folate-free medium containing thymidine (10 μM) and hypoxanthine (100 μM). After 72 h of drug exposure, the number of parasites inside the cells was quantitated by indirect immunofluorescence microscopy. Sixteen compounds had IC ₅₀ s of <3 μM, and five of these had IC ₅₀ s of <0.3 μM and thus were comparable in potency to trimetrexate. The finding that submicromolar concentrations of several of the compounds in the library could inhibit in vitro growth of C. parvum in host cells in the presence of thymidine (dThd) and hypoxanthine (Hx) suggests that lipophilic DHFR inhibitors, in combination with leucovorin, may find use in the treatment of intractable C. parvum infections.

  摘要 对 93 种亲脂性二环和三环二氨基嘧啶衍生物的结构多样性文库进行了测试，以检测其抑制从人和牛分离的副隐孢子虫中克隆的重组二氢叶酸还原酶（DHFR）的能力。 副猪隐孢子虫 (J. R. Vásquez et al., Mol. Biochem. Parasitol. 79:153-165, 1996)。与此同时，该文库还针对人类 DHFR 进行了测试，并与来自 大肠杆菌 .五成抑制浓度（IC 50 s）是通过以二氢叶酸和 NADPH 为共底物的 DHFR 活性标准分光光度法测定的。在测试的化合物中，25 个化合物的 IC 50 在 1 至 10 μM 范围内，对一种或两种 C. parvum 因此与三甲氧苄啶（IC 50 s，约为 4 μM）没有本质区别。另外 25 种化合物的 IC 50 s 为 1.0 μM，其中 9 种化合物的 IC 50 为 0.1 μM，因此药效至少是三甲氧苄啶的 40 倍。其余 42 种化合物为弱抑制剂（IC 50 s，>10 μM），因此不被认为是对这种生物有用的药物。分光光度法酶抑制测定的结果与最近在酵母互补测定中获得的结果之间通常具有良好的相关性（V. H. Brophy 等人，Antimicrob.Agents Chemother.44:1019-1028, 2000; H. Lau et al.Agents Chemother.45:187-195, 2001).虽然文库中的许多化合物都比三甲氧苄氨嘧啶更有效，但没有一种化合物具有三甲氧苄氨嘧啶对副猪嗜血杆菌的选择性。 副猪嗜血杆菌 对人类 DHFR 的选择性。总之，这些检测结果构成了目前最大的亲脂性抗酚化合物潜在抗隐孢子虫药物数据库。该化合物库中的化合物还作为细胞内副猪嗜血杆菌增殖抑制剂进行了测试。 副猪嗜血杆菌 卵囊在含有胸苷（10 μM）和次黄嘌呤（100 μM）的无叶酸培养基中培养的犬肾上皮细胞中的增殖抑制剂。药物暴露 72 小时后，通过间接免疫荧光显微镜对细胞内的寄生虫数量进行量化。16种化合物的IC 50 为 <3 μM，其中五个化合物的 IC 50 s 为 <0.3 μM，因此其效力与三甲曲沙相当。研究发现，库中几种亚摩尔浓度的化合物可抑制副嗜血杆菌的体外生长。 副猪嗜血杆菌 在胸苷（dThd）和次黄嘌呤（Hx）存在的宿主细胞中的体外生长。 C. parvum 感染。
• Cooperative N-Heterocyclic Carbene/Nickel-Catalyzed Hydroacylation of 1,3-Dienes with Aldehydes in Water
  作者：Hao Liu、You-Feng Han、Zhong-Hua Gao、Chun-Lin Zhang、Congyang Wang、Song Ye

  DOI：10.1021/acscatal.1c05517

  日期：2022.2.4

  carbene/nickel-catalyzed redox-neutral hydroacylation of 1,3-dienes with aldehydes in water was reported. A wide range of aliphatic and aromatic aldehydes were directly coupled with 1,3-dienes, providing synthetically useful β,γ-unsaturated ketones or the corresponding ketones after hydrogenation in moderate to high yields and high atom economy. This protocol first demonstrated the compatibility of NHC catalysis

  报道了1,3-二烯与醛在水中的协同N-杂环卡宾/镍催化的氧化还原中性氢化酰化。多种脂肪族和芳香族醛与 1,3-二烯直接偶联，以中等至高产率和高原子经济性提供合成有用的β,γ-不饱和酮或氢化后的相应酮。该协议首先证明了 NHC 催化与镍催化的相容性。水被用作唯一的溶剂，这在协同金属/有机催化体系中很少被报道。
• Fused Heterocyclic Derivatives and Use Thereof
  申请人：Imamura Shinichi

  公开号：US20090137580A1

  公开（公告）日：2009-05-28

  The present invention provides a fused heterocyclic derivative showing a potent kinase inhibitory activity and use thereof. A compound represented by the formula: wherein ring A is an optionally substituted pyrrole ring, X is an optionally substituted CH, Y is an optionally substituted CH or nitrogen atom, Z is an optionally substituted divalent hydrocarbon group or optionally substituted divalent heterocyclic group, T is a single bond or an optionally substituted C 1-3 alkylene group, and U is an optionally substituted amido group, an optionally substituted sulfonamido group, an optionally substituted ureido group, an optionally substituted carbamoyl group or an optionally substituted thioureido group, or a salt thereof, and a pharmaceutical agent containing the compound or a prodrug thereof, which is a kinase (VEGFR, VEGFR2, PDGFR, TIE2) inhibitor, an angiogenesis inhibitor, an agent for the prophylaxis or treatment of cancer, an agent for inhibiting growth of cancer or an agent for suppressing metastasis of cancer.

  本发明提供了一种融合的杂环衍生物，具有强大的激酶抑制活性及其用途。该化合物由以下公式表示： 其中，环A是可选的取代吡咯环，X是可选的取代的CH，Y是可选的取代的CH或氮原子，Z是可选的取代的二价碳氢基团或可选的取代的二价杂环基团，T是单键或可选的取代的C1-3烷基团，U是可选的取代的酰胺基团、可选的取代的磺酰胺基团、可选的取代的脲基团、可选的取代的氨基甲酰基团或可选的取代的硫脲基团，或其盐，以及含有该化合物或其前药的药物制剂，该制剂是激酶(VEGFR、VEGFR2、PDGFR、TIE2)抑制剂、血管生成抑制剂、预防或治疗癌症的药物、抑制癌症生长的药物或抑制癌症转移的药物。